This article has been corrected: The correct 10 th reference is given below:
10. Eyre TA, et al. Cancer. 2019; 125:99-108. https:doi.org/10.1002/cncr.31791.
Oncotarget. 2018; 9:37280-37281. https://doi.org/10.18632/oncotarget.26460
. 2019 Feb 26;10(17):1661. doi: 10.18632/oncotarget.26767
Correction: Predictive biomarkers for disease sensitivity in lymphoma – the holy grail for HDAC inhibitors?
Toby A Eyre
1
Toby A Eyre
1Early Phase Trials Unit, University of Oxford, Oxford, UK; Department of Clinical Haematology, Oxford Cancer Centre, Churchill Hospital, Oxford, UK
Find articles by Toby A Eyre
1Early Phase Trials Unit, University of Oxford, Oxford, UK; Department of Clinical Haematology, Oxford Cancer Centre, Churchill Hospital, Oxford, UK
Collection date 2019 Feb 26.
Copyright: © 2019 Eyre et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PMCID: PMC6422189 PMID: 30899436
This corrects the article "Predictive biomarkers for disease sensitivity in lymphoma – the holy grail for HDAC inhibitors?" in volume 9 on page 37280.